Non-vitamin K oral anticoagulants

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Åke Wiberg Stiftelse and 7 more

Humans1

Outcomes

Mortality

downin humans1HR 0.81

1 study

Non-vitamin K oral anticoagulants decrease mortality in humans (HR 0.81, 95% CI 0.72-0.91).
Humansin patients with AF and AD
Oral anticoagulants, cognition, and clinical outcomes in atrial fibrillation and Alzheimer's disease: a Swedish nationwide study
European heart journal12 Aug 2026

Cognitive decline

downin humans1

1 study

Non-vitamin K oral anticoagulants decrease cognitive decline in humans (β = 0.23 points/year, 95% CI 0.11-0.36).
Humansin patients with AF and AD
Oral anticoagulants, cognition, and clinical outcomes in atrial fibrillation and Alzheimer's disease: a Swedish nationwide study
European heart journal12 Aug 2026

Associations

Fracture

downin humans1HR 0.79

1 study

Non-vitamin K oral anticoagulants lower the risk of fracture in humans (HR 0.79, 95% CI 0.64-0.97).
Humansin patients with AF and AD
Oral anticoagulants, cognition, and clinical outcomes in atrial fibrillation and Alzheimer's disease: a Swedish nationwide study
European heart journal12 Aug 2026

Ischaemic stroke/systemic embolism

downin humans1HR 0.66

1 study

Non-vitamin K oral anticoagulants lower the risk of ischaemic stroke/systemic embolism in humans (HR 0.66, 95% CI 0.53-0.82).
Humansin patients with AF and AD
Oral anticoagulants, cognition, and clinical outcomes in atrial fibrillation and Alzheimer's disease: a Swedish nationwide study
European heart journal12 Aug 2026

Latest

1 in 12 months

European Heart Journal12 Aug

Oral anticoagulants, cognition, and clinical outcomes in atrial fibrillation and Alzheimer's disease: a Swedish nationwide study

Cohort study of 7,308 peopleAtrial fibrillation

Paper

Non-vitamin K oral anticoagulants

Outcomes

Associations

Latest

Oral anticoagulants, cognition, and clinical outcomes in atrial fibrillation and Alzheimer's disease: a Swedish nationwide study

Related